TO STUDY THE EFFECT OF ANTENATAL MAGNESIUM SULPHATE FOR NEUROPROTECTION IN PRETERM BABIES

Background: Antenatal administration of magnesium sulfate is an important part of the neuroprotective strategy for preterm infants. Strong evidence from five randomized controlled trials and five meta-analyses has demonstrated that magnesium sulfate, when administered before preterm delivery, significantly reduces the risk of neurological disabilities. In our study, we aimed at assessing the effectiveness and safety of antenatal magnesium sulphate for neuroprotection in the preterm babies. Methods: This was a prospective randomized controlled trial conducted on 586 women in preterm labour during the period of January 2019 to 2020 attending opd in the department of obstetrics & gynecology at Patna medical college and hospital in 2019.They were randomly allocated into 2 groups. Group A : received magnesium sulphate as neuroprotective agent Group B: received sodium chloride solution. Procedure efficacy(defined as incidence of neurological disabilities, mortality and resuscitative measures in both groups), safety and side effects were assessed in both groups. Results: Babies developing neurological disabilities were less in magnesium sulphate group than sodium chloride groupwhich is statistically insignificant.Total mortality in group A was 137 whereas in group B is 169 which is statistically insignificant.1 neonatehad intraventricular hemorrhage in group A while 4 in group B which is statistically insignificant.. Conclusion: Although various studies have suggested that magnesiumsulphateis cost effective and efficient neuroprotective agent in preterm babies but in our study we could not find significant difference between magnesium and placebo group , but it is proved to be efficient in preventing intraventricular hemorrhage .